From GlobeNewswire: 2024-06-02 10:55:00

Seer, Inc. announced that PrognomiQ completed a groundbreaking mass spectrometry plasma biomarker study, detecting over 13,000 protein groups in plasma from 2,840 subjects. PrognomiQ collected blood samples across 77 U.S. sites and processed them using Seer Proteograph SP100 instruments. The study showcased the power of combined proteomics technologies for early cancer detection. Dr. Bruce Wilcox of PrognomiQ will present the findings at the ASMS Conference on June 6. Thermo Fisher and Seer collaborate on proteomics research, with Seer’s CEO Omid Farokhzad emphasizing the study’s impact and potential for transformative research in healthcare.



Read more at GlobeNewswire: Seer Technology Access Center Provides Unprecedented Scale